484 lines
No EOL
153 KiB
HTML
484 lines
No EOL
153 KiB
HTML
<?xml version="1.0" encoding="utf-8"?>
|
||
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
||
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
||
|
||
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
||
<!-- AppResources meta begin -->
|
||
<meta name="paf-app-resources" content="" />
|
||
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
||
|
||
<!-- AppResources meta end -->
|
||
|
||
<!-- TemplateResources meta begin -->
|
||
<meta name="paf_template" content="" />
|
||
|
||
<!-- TemplateResources meta end -->
|
||
|
||
<!-- Logger begin -->
|
||
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK464278" /><meta name="ncbi_domain" content="pdqcis" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK464278.2/" /><meta name="ncbi_pagename" content="Cognitive Impairment in Adults with Non−Central Nervous System Cancers (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
|
||
<!-- Logger end -->
|
||
|
||
<title>Cognitive Impairment in Adults with Non−Central Nervous System Cancers (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf</title>
|
||
|
||
<!-- AppResources external_resources begin -->
|
||
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
||
|
||
<!-- AppResources external_resources end -->
|
||
|
||
<!-- Page meta begin -->
|
||
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="PDQ Cancer Information Summaries [Internet]" /><meta name="citation_title" content="Cognitive Impairment in Adults with Non−Central Nervous System Cancers (PDQ®)" /><meta name="citation_publisher" content="National Cancer Institute (US)" /><meta name="citation_date" content="2017/11/02" /><meta name="citation_author" content="PDQ Supportive and Palliative Care Editorial Board" /><meta name="citation_pmid" content="29112351" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK464278/" /><meta name="citation_keywords" content="cognitive intervention" /><meta name="citation_keywords" content="cognitive impairment" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Cognitive Impairment in Adults with Non−Central Nervous System Cancers (PDQ®)" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Cancer Institute (US)" /><meta name="DC.Contributor" content="PDQ Supportive and Palliative Care Editorial Board" /><meta name="DC.Date" content="2017/11/02" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK464278/" /><meta name="description" content="Expert-reviewed information summary about cognitive impairment in cancer patients versus normal cognition, and interventions to manage cognition changes" /><meta name="og:title" content="Cognitive Impairment in Adults with Non−Central Nervous System Cancers (PDQ®)" /><meta name="og:type" content="book" /><meta name="og:description" content="Expert-reviewed information summary about cognitive impairment in cancer patients versus normal cognition, and interventions to manage cognition changes" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK464278/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-pdqcis-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/pdqcis/CDR0000788906/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK464278/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script><meta name="book-collection" content="NONE" />
|
||
|
||
<!-- Page meta end -->
|
||
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8EAAB57C974D910000000000B60090.m_13" />
|
||
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/4207974/4206132/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
||
<body class="book-part">
|
||
<div class="grid">
|
||
<div class="col twelve_col nomargin shadow">
|
||
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
||
<div class="sysmessages">
|
||
<noscript>
|
||
<p class="nojs">
|
||
<strong>Warning:</strong>
|
||
The NCBI web site requires JavaScript to function.
|
||
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
||
</p>
|
||
</noscript>
|
||
</div>
|
||
<!--/.sysmessage-->
|
||
<div class="wrap">
|
||
<div class="page">
|
||
<div class="top">
|
||
<div id="universal_header">
|
||
<section class="usa-banner">
|
||
<div class="usa-accordion">
|
||
<header class="usa-banner-header">
|
||
<div class="usa-grid usa-banner-inner">
|
||
<img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
|
||
<p>An official website of the United States government</p>
|
||
<button class="non-usa-accordion-button usa-banner-button" aria-expanded="false" aria-controls="gov-banner-top" type="button">
|
||
<span class="usa-banner-button-text">Here's how you know</span>
|
||
</button>
|
||
</div>
|
||
</header>
|
||
<div class="usa-banner-content usa-grid usa-accordion-content" id="gov-banner-top" aria-hidden="true">
|
||
<div class="usa-banner-guidance-gov usa-width-one-half">
|
||
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg" alt="Dot gov" />
|
||
<div class="usa-media_block-body">
|
||
<p>
|
||
<strong>The .gov means it's official.</strong>
|
||
<br />
|
||
Federal government websites often end in .gov or .mil. Before
|
||
sharing sensitive information, make sure you're on a federal
|
||
government site.
|
||
</p>
|
||
</div>
|
||
</div>
|
||
<div class="usa-banner-guidance-ssl usa-width-one-half">
|
||
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg" alt="Https" />
|
||
<div class="usa-media_block-body">
|
||
<p>
|
||
<strong>The site is secure.</strong>
|
||
<br />
|
||
The <strong>https://</strong> ensures that you are connecting to the
|
||
official website and that any information you provide is encrypted
|
||
and transmitted securely.
|
||
</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
<div class="usa-overlay"></div>
|
||
<header class="ncbi-header" role="banner" data-section="Header">
|
||
|
||
<div class="usa-grid">
|
||
<div class="usa-width-one-whole">
|
||
|
||
<div class="ncbi-header__logo">
|
||
<a href="/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
|
||
<img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
|
||
</a>
|
||
</div>
|
||
|
||
<div class="ncbi-header__account">
|
||
<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
|
||
<button id="account_info" class="header-button" style="display:none" aria-controls="account_popup" type="button">
|
||
<span class="fa fa-user" aria-hidden="true">
|
||
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="20px" height="20px">
|
||
<g style="fill: #fff">
|
||
<ellipse cx="12" cy="8" rx="5" ry="6"></ellipse>
|
||
<path d="M21.8,19.1c-0.9-1.8-2.6-3.3-4.8-4.2c-0.6-0.2-1.3-0.2-1.8,0.1c-1,0.6-2,0.9-3.2,0.9s-2.2-0.3-3.2-0.9 C8.3,14.8,7.6,14.7,7,15c-2.2,0.9-3.9,2.4-4.8,4.2C1.5,20.5,2.6,22,4.1,22h15.8C21.4,22,22.5,20.5,21.8,19.1z"></path>
|
||
</g>
|
||
</svg>
|
||
</span>
|
||
<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
|
||
<span class="sr-only">Show account info</span>
|
||
</button>
|
||
</div>
|
||
|
||
<div class="ncbi-popup-anchor">
|
||
<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
|
||
<div class="ncbi-popup-head">
|
||
<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu" type="button">
|
||
<span class="fa fa-times">
|
||
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" height="24px">
|
||
<path d="M38 12.83l-2.83-2.83-11.17 11.17-11.17-11.17-2.83 2.83 11.17 11.17-11.17 11.17 2.83 2.83 11.17-11.17 11.17 11.17 2.83-2.83-11.17-11.17z"></path>
|
||
</svg>
|
||
</span>
|
||
<span class="usa-sr-only">Close</span></button>
|
||
<h4>Account</h4>
|
||
</div>
|
||
<div class="account-user-info">
|
||
Logged in as:<br />
|
||
<b><span class="username" id="uname_long">username</span></b>
|
||
</div>
|
||
<div class="account-links">
|
||
<ul class="usa-unstyled-list">
|
||
<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
|
||
<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
|
||
<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
|
||
<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
</div>
|
||
</header>
|
||
<div role="navigation" aria-label="access keys">
|
||
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
|
||
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
|
||
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
|
||
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
|
||
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
|
||
</div>
|
||
<section data-section="Alerts">
|
||
<div class="ncbi-alerts-placeholder"></div>
|
||
</section>
|
||
</div>
|
||
<div class="header">
|
||
<div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
|
||
<div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" data-ac_dict="bookshelf-search">Books</option><option value="nlmcatalog">NLM Catalog</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
|
||
<a href="/books/browse/">Browse Titles</a>
|
||
</li><li>
|
||
<a href="/books/advanced/">Advanced</a>
|
||
</li><li class="help">
|
||
<a href="/books/NBK3833/">Help</a>
|
||
</li><li class="disclaimer">
|
||
<a target="_blank" data-ga-category="literature_resources" data-ga-action="link_click" data-ga-label="disclaimer_link" href="https://www.ncbi.nlm.nih.gov/books/about/disclaimer/">Disclaimer</a>
|
||
</li></ul></div>
|
||
</div>
|
||
|
||
|
||
|
||
<!--<component id="Page" label="headcontent"/>-->
|
||
|
||
</div>
|
||
<div class="content">
|
||
<!-- site messages -->
|
||
<!-- Custom content 1 -->
|
||
<div class="col1">
|
||
|
||
</div>
|
||
|
||
<div class="container">
|
||
<div id="maincontent" class="content eight_col col">
|
||
<!-- Custom content in the left column above book nav -->
|
||
<div class="col2">
|
||
|
||
</div>
|
||
|
||
<!-- Book content -->
|
||
|
||
|
||
<!-- Custom content between navigation and content -->
|
||
<div class="col3">
|
||
|
||
</div>
|
||
|
||
<div class="document">
|
||
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="Table of Contents Page" href="/books/n/pdqcis/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-pdqcis-lrg.png" alt="Cover of PDQ Cancer Information Summaries" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>PDQ Cancer Information Summaries [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK464278_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK464278_dtls__"><div>Bethesda (MD): <a href="http://www.cancer.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Cancer Institute (US)</a>; 2002-.</div></div><div class="half_rhythm"></div><div class="bk_noprnt"><form method="get" action="/books/n/pdqcis/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div></div></div></div>
|
||
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK464278_"><span class="title" itemprop="name">Cognitive Impairment in Adults with Non−Central Nervous System Cancers (PDQ®)</span></h1><div class="subtitle whole_rhythm">Health Professional Version</div><p class="contrib-group"><span itemprop="author">PDQ Supportive and Palliative Care Editorial Board</span>.</p><p class="small">Published online: March 14, 2018.</p><p class="small">Created: <span itemprop="datePublished">November 2, 2017</span>.</p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="_abs_rndgid_" itemprop="description"><p id="CDR0000788906__8">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about cognitive impairment in adults with cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.</p><p id="CDR0000788906__9">This summary is reviewed regularly and updated as necessary by the PDQ Supportive and Palliative Care Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p></div><div id="CDR0000788906__1"><h2 id="_CDR0000788906__1_">General Information About Cognitive Impairment in Cancer Survivors</h2><p id="CDR0000788906__2">Cancer survivors experience more-than-expected symptoms related to cognitive impairment.[<a class="bk_pop" href="#CDR0000788906_rl_1_1">1</a>] Formal neuropsychological testing demonstrates a range of objective cognitive deficits in some but not all survivors who report symptoms, compared with healthy control subjects; these deficits include faulty memory, deficits in concentration, decreased rates of information processing, and reduced executive function.[<a class="bk_pop" href="#CDR0000788906_rl_1_1">1</a>-<a class="bk_pop" href="#CDR0000788906_rl_1_3">3</a>] Furthermore, subjective reports of cognitive impairment often do not correlate with the results of formal neuropsychological testing.[<a class="bk_pop" href="#CDR0000788906_rl_1_4">4</a>,<a class="bk_pop" href="#CDR0000788906_rl_1_5">5</a>] Finally, the risk factors for subjective or objective cognitive impairment—such as age, preexisting cognitive function, type of cancer, type of chemotherapy, and the natural history of the impairments—remain a matter of active investigation.</p><p id="CDR0000788906__3">The oncology clinician will care for survivors with objective or subjective cognitive impairment and is advised to consider the following:</p><ul id="CDR0000788906__4"><li class="half_rhythm"><div>Because <i>abnormal</i> is defined as significant deviation from population means, formal neuropsychological testing may be insensitive to subtle changes from prediagnosis or pretreatment cognitive function.</div></li><li class="half_rhythm"><div>There is a strong correlation between patient subjective reports of cognitive impairment and decreased daily functioning [<a class="bk_pop" href="#CDR0000788906_rl_1_6">6</a>] or reduced quality of life.[<a class="bk_pop" href="#CDR0000788906_rl_1_7">7</a>]</div></li><li class="half_rhythm"><div>It is not known whether cognitive impairment influences psychological distress or is a sign of psychological distress.[<a class="bk_pop" href="#CDR0000788906_rl_1_4">4</a>] Studies have shown that cognitive impairment is associated with negative emotional states such as anxiety and depression,[<a class="bk_pop" href="#CDR0000788906_rl_1_6">6</a>,<a class="bk_pop" href="#CDR0000788906_rl_1_8">8</a>,<a class="bk_pop" href="#CDR0000788906_rl_1_9">9</a>] the personality trait of negative affectivity,[<a class="bk_pop" href="#CDR0000788906_rl_1_10">10</a>] and self-perceived treatment burden.[<a class="bk_pop" href="#CDR0000788906_rl_1_8">8</a>]</div></li><li class="half_rhythm"><div>Treatments for patients with cancer-related cognitive impairment have shown minimal to modest benefit. Therefore, compassionate acknowledgment of the concerns and a supportive approach are essential.</div></li></ul><div id="CDR0000788906_rl_1"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000788906_rl_1_1">Jean-Pierre P, Winters PC, Ahles TA, et al.: Prevalence of self-reported memory problems in adult cancer survivors: a national cross-sectional study. J Oncol Pract 8 (1): 30-4, 2012. [<a href="/pmc/articles/PMC3266313/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3266313</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22548008" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22548008</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_1_2">Vardy JL, Dhillon HM, Pond GR, et al.: Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. J Clin Oncol 33 (34): 4085-92, 2015. [<a href="/pmc/articles/PMC5683012/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5683012</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26527785" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26527785</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_1_3">Scherwath A, Schirmer L, Kruse M, et al.: Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. Psychooncology 22 (7): 1509-16, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/22945857" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22945857</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_1_4">Pullens MJ, De Vries J, Roukema JA: Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology 19 (11): 1127-38, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20020424" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20020424</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_1_5">Hutchinson AD, Hosking JR, Kichenadasse G, et al.: Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38 (7): 926-34, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22658913" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22658913</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_1_6">Shilling V, Jenkins V: Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 11 (1): 6-15, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/16844416" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16844416</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_1_7">Von Ah D, Habermann B, Carpenter JS, et al.: Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs 17 (2): 236-41, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/22901546" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22901546</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_1_8">Hermelink K, Küchenhoff H, Untch M, et al.: Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 19 (12): 1321-8, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20127909" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20127909</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_1_9">Hermelink K, Untch M, Lux MP, et al.: Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109 (9): 1905-13, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17351951" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17351951</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_1_10">Watson D, Pennebaker JW: Health complaints, stress, and distress: exploring the central role of negative affectivity. Psychol Rev 96 (2): 234-54, 1989. [<a href="https://pubmed.ncbi.nlm.nih.gov/2710874" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2710874</span></a>]</div></li></ol></div></div><div id="CDR0000788906__10"><h2 id="_CDR0000788906__10_">Normal Cognition</h2><p id="CDR0000788906__11"><i>Cognition</i> is the mental process of acquiring knowledge and understanding through thought, experience, and the senses. The six domains of cognitive function summarized below were proposed in the <i>Diagnostic and Statistical Manual of Mental Disorders,</i> 5th edition (DSM-5), to help establish the etiology and severity of neurocognitive disorders.[<a class="bk_pop" href="#CDR0000788906_rl_10_1">1</a>]</p><ul id="CDR0000788906__12"><li class="half_rhythm"><div><b>Attention and concentration:</b> Ability to triage relevant information, thoughts, and actions while ignoring distractions; and the ability to maintain attention for an extended period of time.</div></li><li class="half_rhythm"><div><b>Executive function:</b> Ability to initiate and generate hypotheses, to plan, and to make decisions.</div></li><li class="half_rhythm"><div><b>Information processing speed:</b> Ability to quickly and efficiently process information.</div></li><li class="half_rhythm"><div><b>Visuospatial skill:</b> Ability to process and interpret visual information about where things are in space.</div></li><li class="half_rhythm"><div><b>Language:</b> Ability to comprehend and communicate symbolic information, either verbally or in writing.</div></li><li class="half_rhythm"><div><b>Learning and memory:</b> Ability to acquire new information; and ability to store and recall new information, in either the short term or the long term.</div></li></ul><p id="CDR0000788906__13">The domains are interdependent, and any proposed taxonomy is provisional and will depend on the specific neuropsychological tests employed in assessment. Furthermore, there is heterogeneity among published studies on what scales are combined into a single score and the cutoff for impairment. While the domains reasonably capture the range of concerns experienced by people with cancer, it is important to clarify the specific impairment through a careful history or formal testing. In addition, comparisons between studies are hampered by different scales and definitions.</p><div id="CDR0000788906_rl_10"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000788906_rl_10_1">Sachdev PS, Blacker D, Blazer DG, et al.: Classifying neurocognitive disorders: the DSM-5 approach. Nat Rev Neurol 10 (11): 634-42, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/25266297" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25266297</span></a>]</div></li></ol></div></div><div id="CDR0000788906__14"><h2 id="_CDR0000788906__14_">Responding to Patient Reports of Cognitive Impairment</h2><p id="CDR0000788906__15">Cancer patients may experience the following difficulties:</p><ul id="CDR0000788906__16"><li class="half_rhythm"><div>Difficulty multitasking; must focus on one thing at a time.</div></li><li class="half_rhythm"><div>Trouble concentrating.</div></li><li class="half_rhythm"><div>Memory lapses.</div></li><li class="half_rhythm"><div>Inability to focus on tasks.</div></li><li class="half_rhythm"><div>Difficulty following instructions.</div></li><li class="half_rhythm"><div>Decreased ability to handle personal finances.</div></li><li class="half_rhythm"><div>Disorganized behavior or thinking.</div></li><li class="half_rhythm"><div>Loss of initiative.</div></li><li class="half_rhythm"><div>Difficulty remembering common words and recalling names.</div></li><li class="half_rhythm"><div>Inability to recognize familiar objects.</div></li><li class="half_rhythm"><div>Altered perception.</div></li><li class="half_rhythm"><div>Difficulty finding words.</div></li></ul><p id="CDR0000788906__17">Before a patient is referred for formal neuropsychological testing, the oncology clinician can perform a complete assessment of the potential contribution of medications and medical comorbidities to the patient’s experience. It is well established that preexisting illness may contribute to cognitive impairment before a patient is diagnosed with or treated for cancer.[<a class="bk_pop" href="#CDR0000788906_rl_14_1">1</a>] Patients who report symptoms or concerns suggestive of cognitive impairment may benefit from evaluation of potentially reversible causes and the taking of appropriate measures. Potential contributing factors include the following:</p><ul id="CDR0000788906__18"><li class="half_rhythm"><div>Age.</div></li><li class="half_rhythm"><div>Frailty.[<a class="bk_pop" href="#CDR0000788906_rl_14_2">2</a>,<a class="bk_pop" href="#CDR0000788906_rl_14_3">3</a>]</div></li><li class="half_rhythm"><div>Medications and their side effects.</div></li><li class="half_rhythm"><div>Hormone status and menopause status.</div></li><li class="half_rhythm"><div>Emotional distress and/or depressive symptoms and anxiety.</div></li><li class="half_rhythm"><div>Symptom burden such as pain, fatigue, and sleep disturbance.</div></li><li class="half_rhythm"><div>Comorbidities.</div></li><li class="half_rhythm"><div>Use of alcohol or other agents that alter cognition.</div></li></ul><div id="CDR0000788906__19"><h3>Validation of the Survivor Experience</h3><p id="CDR0000788906__20">The experience of cognitive changes after cancer treatment has been documented in qualitative research.[<a class="bk_pop" href="#CDR0000788906_rl_14_4">4</a>-<a class="bk_pop" href="#CDR0000788906_rl_14_7">7</a>] Concerns reported by survivors include memory problems, inability to concentrate, and decreased ability to function in daily activities, including employment.[<a class="bk_pop" href="#CDR0000788906_rl_14_4">4</a>] Survivors expressed frustration with the lack of acknowledgement by health care providers and expressed the need to be informed early about the possibility of developing this problem and for validation when they experience it.[<a class="bk_pop" href="#CDR0000788906_rl_14_5">5</a>,<a class="bk_pop" href="#CDR0000788906_rl_14_6">6</a>] Patients found it comforting that these subtle mental changes have been observed widely and are to be expected. The least helpful response by practitioners was minimizing the changes and/or not taking them seriously.[<a class="bk_pop" href="#CDR0000788906_rl_14_5">5</a>]</p></div><div id="CDR0000788906__21"><h3>Evaluation of Subjective Reports of Cognitive Impairment</h3><p id="CDR0000788906__22">As with all patient-reported symptoms and signs, a thorough evaluation will help determine the cause of cognitive impairment and define potential interventions to reverse the symptoms or stabilize the patient. A focused history and physical examination will assess the following:</p><ul id="CDR0000788906__23"><li class="half_rhythm"><div>Measures of baseline cognitive function, such as educational attainment, job-related responsibilities, and premorbid functioning.</div></li><li class="half_rhythm"><div>Likelihood of cognitive impairment based on potential risk factors such as age; type and stage of cancer; and treatment history, including time since last treatment and drugs used in treatment.</div></li><li class="half_rhythm"><div>Use or misuse of prescription and over-the-counter medications and supplements.</div></li><li class="half_rhythm"><div>Focal neurologic deficits. Focal motor defects or discrete cortical defects such as aphasia or apraxia are uncommon in cancer-associated cognitive impairment.[<a class="bk_pop" href="#CDR0000788906_rl_14_8">8</a>]</div></li><li class="half_rhythm"><div>Signs of metastatic disease to the brain, meninges, or both.</div></li></ul><p id="CDR0000788906__24">The routine use of neuroimaging is not warranted unless there are concerns for specific complications from the cancer or its treatment, e.g., metastatic cancer to the brain.</p></div><div id="CDR0000788906_rl_14"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000788906_rl_14_1">Mandelblatt JS, Stern RA, Luta G, et al.: Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J Clin Oncol 32 (18): 1909-18, 2014. [<a href="/pmc/articles/PMC4050204/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4050204</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24841981" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24841981</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_14_2">Mandelblatt JS, Jacobsen PB, Ahles T: Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors. J Clin Oncol 32 (24): 2617-26, 2014. [<a href="/pmc/articles/PMC4129505/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4129505</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25071135" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25071135</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_14_3">Mandelblatt JS, Clapp JD, Luta G, et al.: Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). Cancer : , 2016. [<a href="/pmc/articles/PMC5113662/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5113662</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27447359" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27447359</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_14_4">Myers JS: Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum 39 (1): E31-40, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22201666" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22201666</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_14_5">Boykoff N, Moieni M, Subramanian SK: Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 3 (4): 223-32, 2009. [<a href="/pmc/articles/PMC2775113/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2775113</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19760150" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19760150</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_14_6">Von Ah D, Habermann B, Carpenter JS, et al.: Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs 17 (2): 236-41, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/22901546" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22901546</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_14_7">Munir F, Burrows J, Yarker J, et al.: Women's perceptions of chemotherapy-induced cognitive side affects on work ability: a focus group study. J Clin Nurs 19 (9-10): 1362-70, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20500346" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20500346</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_14_8">Wefel JS, Witgert ME, Meyers CA: Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev 18 (2): 121-31, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18415683" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18415683</span></a>]</div></li></ol></div></div><div id="CDR0000788906__25"><h2 id="_CDR0000788906__25_">Proactive Approaches to Cognitive Impairment</h2><p id="CDR0000788906__26">In addition to responding respectfully and compassionately to patients’ concerns about cognitive impairment, the oncology clinician faces questions on how best to inform patients about the risks of cognitive impairment and whether to routinely screen all patients, or limit screening to patients at higher risk.</p><div id="CDR0000788906__27"><h3>Education About the Risk of Cognitive Impairment</h3><p id="CDR0000788906__28">In-depth interviews with cancer survivors revealed that few materials were available to educate them about cognitive problems.[<a class="bk_pop" href="#CDR0000788906_rl_25_1">1</a>] The amount of information desired by survivors varied from extensive to brief and general.[<a class="bk_pop" href="#CDR0000788906_rl_25_2">2</a>] The optimal method of information delivery was also not clear. Patients and survivors described feeling overwhelmed by the amount of written information about treatment and side effects that they received; some patients expressed the desire to discuss their preferred method of learning with a health care provider who would provide information in a relaxed, unhurried manner.</p><p id="CDR0000788906__29">One study examined the influence of priming patients to associate chemotherapy treatment with the experience of cognitive impairment. Via cancer websites, investigators recruited 150 cancer patients who were receiving or had received chemotherapy and 86 patients who had no experience with chemotherapy.[<a class="bk_pop" href="#CDR0000788906_rl_25_3">3</a>] Volunteers were asked to participate in a study on the effects of cancer therapies on individual patients and were randomly assigned to receive a neutral introduction or a priming introduction that stated “some patients treated with chemotherapy experience cognitive problems.”</p><p id="CDR0000788906__30">The study found an association between priming and having had chemotherapy; patients who had experience with chemotherapy and who received the priming introduction reported higher levels of cognitive impairment.[<a class="bk_pop" href="#CDR0000788906_rl_25_3">3</a>] The volunteers were highly aware of the relationship between chemotherapy and cognitive impairment, but preexisting knowledge of that relationship had no effect
|
||
on self-reported cognitive complaints and neuropsychological test performance. These study results raise the possibility that the test environment introduced an artifact.</p><p id="CDR0000788906__31">The optimal means and content for educating patients about cognitive impairment are not established. The principle of informed consent applies: the oncology clinician must inform patients of the risk in a manner that is respectful of personal autonomy.</p></div><div id="CDR0000788906__32"><h3>Screening</h3><p id="CDR0000788906__33">No large-scale studies of routine screening for cognitive impairment have been published. One challenge is the lack of a brief measure of cognitive function that can accurately assess the multiple domains.[<a class="bk_pop" href="#CDR0000788906_rl_25_4">4</a>] Patient-reported outcome scales (e.g., the Patient-Reported Outcomes Measurement Information System 8-item scale; and the Functional Assessment of Cancer Therapy—Cognitive) might prove valuable, but further study is required. An additional challenge is the timing of screening activities, given the variable time to onset and the resolution of concerns without intervention for many patients.</p></div><div id="CDR0000788906_rl_25"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000788906_rl_25_1">Myers JS: Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum 39 (1): E31-40, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22201666" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22201666</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_25_2">Boykoff N, Moieni M, Subramanian SK: Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 3 (4): 223-32, 2009. [<a href="/pmc/articles/PMC2775113/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2775113</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19760150" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19760150</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_25_3">Schagen SB, Das E, Vermeulen I: Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients. Psychooncology 21 (10): 1132-5, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/21769988" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21769988</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_25_4">Wefel JS, Vardy J, Ahles T, et al.: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12 (7): 703-8, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21354373" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21354373</span></a>]</div></li></ol></div></div><div id="CDR0000788906__34"><h2 id="_CDR0000788906__34_">Research Studies on Prevalence, Risk Factors, and the Natural History of Cognitive Impairment</h2><p id="CDR0000788906__35">Multiple research studies of cognitive impairment have been published. This section summarizes the key findings of meta-analyses, systematic reviews, and individual studies published subsequently.</p><p id="CDR0000788906__36">The International Cognition and Cancer Task Force (ICCTF) has identified several methodological differences or shortcomings in published studies:[<a class="bk_pop" href="#CDR0000788906_rl_34_1">1</a>,<a class="bk_pop" href="#CDR0000788906_rl_34_2">2</a>]</p><ul id="CDR0000788906__37"><li class="half_rhythm"><div>Whether patients enrolled in the study had presented with subjective concerns or were recruited to undergo formal testing.</div></li><li class="half_rhythm"><div>Assessment of pretreatment cognitive impairment and interstudy differences in how baseline function was accounted for.</div></li><li class="half_rhythm"><div>Variations in objective neuropsychological testing, including instruments selected, definitions of cognitive domains, and definition of impairment.</div></li></ul><p id="CDR0000788906__38">The ICCTF has recommended that investigators define a priori cognitive endpoints, use a core of validated neuropsychological tests, adopt common criteria for cognitive impairment, employ a longitudinal design, and use a control population.[<a class="bk_pop" href="#CDR0000788906_rl_34_1">1</a>,<a class="bk_pop" href="#CDR0000788906_rl_34_2">2</a>]</p><div id="CDR0000788906__39"><h3>Meta-Analyses and Systematic Reviews</h3><div id="CDR0000788906__40"><h4>Subjective cognitive concerns in breast cancer patients</h4><p id="CDR0000788906__41">Twenty-seven studies of subjective cognitive impairment in patients with breast cancer published between 1960 and April 2009 were identified by one group of researchers.[<a class="bk_pop" href="#CDR0000788906_rl_34_3">3</a>] Only eight studies were high quality. The percentage of patients reporting subjective concerns ranged from 21% to 90%. There was no correlation between subjective concerns and objective findings, and no conclusive information about timing and the contribution of disease versus treatment received.</p><p id="CDR0000788906__42">Subjective concerns were related to health status, fatigue, and psychological distress. The authors pointed out that those subjective concerns may be a marker of anxiety or depression rather than objective cognitive impairment.[<a class="bk_pop" href="#CDR0000788906_rl_34_3">3</a>]</p></div><div id="CDR0000788906__43"><h4>Relationship between subjective concerns and objective findings</h4><p id="CDR0000788906__44">A comprehensive screen for studies comparing rates of subjective cognitive concerns and objective cognitive impairment published between 1980 and 2012 yielded 24 studies.[<a class="bk_pop" href="#CDR0000788906_rl_34_4">4</a>] Only 8 of the 24 studies demonstrated a significant correlation, and 6 of these involved patients with breast cancer. The authors pointed out that the lack of correlation may be methodologic (different assessment methods, different definitions of significant impairment) or explained by the possibility that subjective concerns are a sign of psychological distress.</p></div><div id="CDR0000788906__45"><h4>Meta-analysis of cognitive impairment in breast cancer survivors</h4><p id="CDR0000788906__46">A group of investigators performed a meta-analysis of data from studies that reported the results of neuropsychological tests in women with breast cancer who were treated for more than 6 months before the study.[<a class="bk_pop" href="#CDR0000788906_rl_34_5">5</a>] The investigators identified 17 studies with 807 patients; the mean time since completion of chemotherapy was 2.9 years. Weighted average effect sizes for the studied cognitive domains demonstrated modest impairment in verbal ability (effect size, –0.19; 95% confidence interval [CI], –0.30 to –0.07; <i>P</i> = .002) and visuospatial ability (effect size, –0.27; 95% CI, –0.45 to –0.08; <i>P</i> = .006).</p></div><div id="CDR0000788906__47"><h4>Chemotherapy and cognitive impairment in patients with cancer</h4><p id="CDR0000788906__48">A group of researchers calculated effect sizes on the basis of data from 13 high-quality studies published in 2010 and earlier.[<a class="bk_pop" href="#CDR0000788906_rl_34_6">6</a>] Key criteria for study inclusion were reports with primary data, statistics to allow calculation of effect sizes, and a control group; studies with patients who had psychological distress were excluded.</p><p id="CDR0000788906__49">Although several domains were affected, the effect sizes were small. The affected domains included executive function (effect size, –0.27), memory (effect size, –0.21), and verbal function and language skills (effect size, –0.17). Insignificant effect sizes were observed for construction (the ability to draw and build), concept formation, reasoning, perception, and orientation and attention.</p><p id="CDR0000788906__50">The authors noted a consistent but not universal trend of worse performance by patients who received chemotherapy compared with groups who received other types of treatment, received no treatment, or were healthy. Furthermore, longer time in treatment was associated with increased impairment, and longer time since completion of treatment was associated with improvement.[<a class="bk_pop" href="#CDR0000788906_rl_34_6">6</a>]</p></div><div id="CDR0000788906__51"><h4>Objective cognitive deficits in men receiving androgen deprivation therapy for prostate cancer</h4><p id="CDR0000788906__52">Researchers identified 14 high-quality studies among 157 potentially relevant articles published between 1950 and June 2012 by searching PubMed, Medline, PsycINFO, Cochrane Library, and Web of Knowledge/Science.[<a class="bk_pop" href="#CDR0000788906_rl_34_7">7</a>] Criteria for study inclusion were an appropriate control group, baseline measurements, and the use of objective neuropsychological tests. Eleven studies were longitudinal; the authors included three cross-sectional studies.</p><p id="CDR0000788906__53">Effect sizes were calculated for the results. The only significant effect detected was for visuomotor ability. There were no discernible negative effects on the other domains studied: attention/working memory, executive functioning, language, verbal memory, visual memory, and visuospatial ability.[<a class="bk_pop" href="#CDR0000788906_rl_34_7">7</a>]</p></div></div><div id="CDR0000788906__54"><h3>Individual Research Studies</h3><div id="CDR0000788906__55"><h4>Formal neuropsychological tests of patients with early-stage breast cancer receiving adjuvant treatment</h4><p id="CDR0000788906__56">Several studies are relevant to an understanding of cognitive impairment in women with early-stage breast cancer who receive chemotherapy.</p><p id="CDR0000788906__57">Employing a battery of neuropsychological and psychological tests, investigators assessed healthy control subjects and women with early-stage breast cancer who were treated with chemotherapy (n = 60) or who did not receive chemotherapy (n = 72), before treatment and then at 1, 6, and 18 months.[<a class="bk_pop" href="#CDR0000788906_rl_34_8">8</a>] The primary outcome of interest was processing speed. Results demonstrated that women aged 60 years or older with lower baseline cognitive reserve who received chemotherapy scored lower on processing speed than did healthy control subjects or women who did not receive chemotherapy. These results are consistent with results from studies of aging.[<a class="bk_pop" href="#CDR0000788906_rl_34_9">9</a>] There was also an effect on verbal ability that resolved by 6 months. There were no demonstrable interactions between time, age, and cognitive reserve for verbal memory, visual memory, working memory, sorting, distractibility, or reaction time.[<a class="bk_pop" href="#CDR0000788906_rl_34_8">8</a>]</p><p id="CDR0000788906__58">Another group of investigators performed neuropsychological assessments on 60 women younger than 66 years who had early-stage breast cancer.[<a class="bk_pop" href="#CDR0000788906_rl_34_10">10</a>] The subjects were tested before and after each cycle of adjuvant chemotherapy. The goal was to determine whether there was progressive decline suggesting a dose-response relationship. A control cohort of 60 healthy women matched for age and education was tested at appropriate intervals. The authors observed a dose-related decline in working memory, processing speed, verbal memory, and visual memory.[<a class="bk_pop" href="#CDR0000788906_rl_34_10">10</a>]</p></div><div id="CDR0000788906__59"><h4>Subjective reports by patients with early-stage breast cancer receiving adjuvant treatment</h4><p id="CDR0000788906__60">Investigators compared subjective cognitive functioning (measured by the Cognitive Failures Questionnaire) and satisfaction with subjective cognitive functioning (measured with the cognitive functioning facet of the World Health Organization Quality of Life instrument) at two times in women with breast cancer—before chemotherapy and 3 months later—and at comparable times in women with benign breast disease.[<a class="bk_pop" href="#CDR0000788906_rl_34_11">11</a>] The frequency of subjective concerns did not differ, but women with breast cancer were less satisfied with their cognitive functioning. Psychological factors and diagnosis influenced satisfaction with cognitive functioning.</p></div><div id="CDR0000788906__61"><h4>Self-reported neurocognitive symptoms in women with breast cancer</h4><p id="CDR0000788906__62">Investigators conducted a longitudinal study of 581 patients with breast cancer recruited from community cancer clinics and compared the results with age-matched control subjects.[<a class="bk_pop" href="#CDR0000788906_rl_34_12">12</a>] Patients and control subjects completed the Functional Assessment of Cancer Therapy—Cognitive Function (FACT-Cog) before receiving chemotherapy, 4 weeks postchemotherapy, and 6 months after the second assessment. Control subjects were tested within the same time windows as patients. Relevant findings were as follows:</p><ul id="CDR0000788906__63"><li class="half_rhythm"><div>At baseline, patients with breast cancer had lower overall quality-of-life scores (on the Functional Assessment of Cancer Therapy: General, or FACT-G) than did control subjects.</div></li><li class="half_rhythm"><div>Mean FACT-G scores declined in patients postchemotherapy but remained stable in control subjects.</div></li><li class="half_rhythm"><div>Almost half of the patients experienced decline in cognitive function, compared with only 10% of control subjects.</div></li><li class="half_rhythm"><div>Predictors for decline on the overall FACT-Cog scale included lower reading scores, higher depression, and higher anxiety.</div></li><li class="half_rhythm"><div>Predictors for decline in specific subscales varied.</div></li></ul></div><div id="CDR0000788906__64"><h4>Longitudinal formal neuropsychological tests of patients with early-stage colon cancer</h4><p id="CDR0000788906__65">Researchers administered formal tests to 81 patients with early-stage colon cancer who were scheduled to receive oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX4) and conducted assessments prechemotherapy (n = 81), postchemotherapy (n = 73), and 6 months after the end of the last cycle of chemotherapy (n = 54).[<a class="bk_pop" href="#CDR0000788906_rl_34_13">13</a>] Attention and visual-motor ability, executive function, verbal memory, and verbal learning were evaluated.</p><p id="CDR0000788906__66">Results demonstrated that more than one-third of patients (37%) had cognitive impairment in processing speed and executive functioning before receiving chemotherapy. More than half of patients (56%) had a decline in verbal memory. At 6 months, 54% of patients had improved, but 33% had worsened. In an exploratory analysis, older age and fewer years of education were risk factors for cognitive impairment. Conversely, quality of life, anxiety, depression, or fatigue levels did not correlate with cognitive dysfunction.[<a class="bk_pop" href="#CDR0000788906_rl_34_13">13</a>]</p></div><div id="CDR0000788906__67"><h4>Longitudinal formal neuropsychological tests of patients with early- and advanced-stage colon cancer</h4><p id="CDR0000788906__68">The longitudinal changes in neuropsychological tests and patient self-reported measures of cognitive symptoms (FACT-Cog version 2) were studied in a cohort of 362 patients with colorectal cancer (289 early-stage and 73 advanced-stage patients) who received chemotherapy (173) or did not receive chemotherapy (116). Results in these patients were compared with results in a control population of 72 subjects.[<a class="bk_pop" href="#CDR0000788906_rl_34_14">14</a>] Salient results included the following:</p><ul id="CDR0000788906__69"><li class="half_rhythm"><div>Self-reported cognitive impairment was more common in patients who received chemotherapy (32%) than in patients who did not receive chemotherapy (16%) or in control subjects (12.5%) (<i>P</i> = .007) at 6 months. There were no differences at 12 months.</div></li><li class="half_rhythm"><div>Patient self-reported cognitive impairment was moderately associated with fatigue, quality of life, and anxiety/depression.</div></li><li class="half_rhythm"><div>Correlation between neuropsychological test results and self-reported impairment was weak.</div></li><li class="half_rhythm"><div>Based on ICCTF criteria, cognitive impairment was present in approximately 50% of patients with colorectal cancer at baseline, 6, and 12 months, compared with approximately 15% of control subjects.</div></li><li class="half_rhythm"><div>There were no differences between patients who had or had not received chemotherapy.</div></li></ul></div><div id="CDR0000788906__70"><h4>Longitudinal neuropsychological tests of men with prostate cancer receiving androgen deprivation therapy</h4><p id="CDR0000788906__71">Investigators studied 58 men with prostate cancer who received androgen deprivation therapy (ADT) at baseline, 6 months, and 12 months and compared their results to those of age-matched and education-level–matched patients with prostate cancer who did not receive ADT (n = 88) and men without prostate cancer (n = 84).[<a class="bk_pop" href="#CDR0000788906_rl_34_15">15</a>] The groups were similar at baseline, but at 6 and 12 months, ADT-treated men were more likely to have impaired cognitive performance according to ICCTF criteria, which combine results from individual tests. Rates of impaired cognitive performance on individual tests, however, were not significantly different at 12 months between ADT-treated patients and control subjects. Age, cognitive reserve, depressive symptoms, fatigue, and hot flashes did not moderate the effect of ADT on cognitive performance.</p></div><div id="CDR0000788906__72"><h4>Longitudinal neuropsychological tests of allogeneic stem cell transplant (SCT) recipients</h4><p id="CDR0000788906__73">Researchers tested 102 transplant recipients before and at 12 months after SCT.[<a class="bk_pop" href="#CDR0000788906_rl_34_16">16</a>] They employed a battery of 14 tests to assess the following cognitive domains: verbal working memory/fluency, fine motor function, visuospatial working memory, verbal learning and retrieval, and reaction time. The investigators chose to report the frequency of below-normal test scores for individual tests rather than define domain-specific performance, so comparison with other studies is not possible.</p><p id="CDR0000788906__74">Some evidence of impairment in at least one domain was present in 47% of subjects at baseline and 41% of subjects at follow-up. Age and premorbid intelligence level were associated with performance. Finally, 16% of patients demonstrated a decline in cognitive function.[<a class="bk_pop" href="#CDR0000788906_rl_34_16">16</a>]</p></div></div><div id="CDR0000788906_rl_34"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000788906_rl_34_1">Wefel JS, Vardy J, Ahles T, et al.: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12 (7): 703-8, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/21354373" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21354373</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_2">Joly F, Giffard B, Rigal O, et al.: Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. J Pain Symptom Manage 50 (6): 830-41, 2015. [<a href="https://pubmed.ncbi.nlm.nih.gov/26344551" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26344551</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_3">Pullens MJ, De Vries J, Roukema JA: Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology 19 (11): 1127-38, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20020424" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20020424</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_4">Hutchinson AD, Hosking JR, Kichenadasse G, et al.: Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38 (7): 926-34, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22658913" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22658913</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_5">Jim HS, Phillips KM, Chait S, et al.: Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30 (29): 3578-87, 2012. [<a href="/pmc/articles/PMC3462044/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3462044</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22927526" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22927526</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_6">Hodgson KD, Hutchinson AD, Wilson CJ, et al.: A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev 39 (3): 297-304, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/23219452" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23219452</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_7">McGinty HL, Phillips KM, Jim HS, et al.: Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer 22 (8): 2271-80, 2014. [<a href="/pmc/articles/PMC4090762/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4090762</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24859915" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24859915</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_8">Ahles TA, Saykin AJ, McDonald BC, et al.: Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28 (29): 4434-40, 2010. [<a href="/pmc/articles/PMC2988635/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2988635</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20837957" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20837957</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_9">Whalley LJ, Deary IJ, Appleton CL, et al.: Cognitive reserve and the neurobiology of cognitive aging. Ageing Res Rev 3 (4): 369-82, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/15541707" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15541707</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_10">Collins B, MacKenzie J, Tasca GA, et al.: Cognitive effects of chemotherapy in breast cancer patients: a dose-response study. Psychooncology 22 (7): 1517-27, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/22936651" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22936651</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_11">Pullens MJ, De Vries J, Van Warmerdam LJ, et al.: Chemotherapy and cognitive complaints in women with breast cancer. Psychooncology 22 (8): 1783-9, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/23109296" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23109296</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_12">Janelsins MC, Heckler CE, Peppone LJ, et al.: Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study. J Clin Oncol 35 (5): 506-514, 2017. [<a href="/pmc/articles/PMC5455314/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5455314</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28029304" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28029304</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_13">Cruzado JA, López-Santiago S, Martínez-Marín V, et al.: Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. Support Care Cancer 22 (7): 1815-23, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/24535240" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24535240</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_14">Vardy JL, Dhillon HM, Pond GR, et al.: Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. J Clin Oncol 33 (34): 4085-92, 2015. [<a href="/pmc/articles/PMC5683012/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5683012</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26527785" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26527785</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_15">Gonzalez BD, Jim HS, Booth-Jones M, et al.: Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison. J Clin Oncol 33 (18): 2021-7, 2015. [<a href="/pmc/articles/PMC4461804/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4461804</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25964245" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25964245</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_34_16">Scherwath A, Schirmer L, Kruse M, et al.: Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. Psychooncology 22 (7): 1509-16, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/22945857" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22945857</span></a>]</div></li></ol></div></div><div id="CDR0000788906__75"><h2 id="_CDR0000788906__75_">Interventions for Cognitive Impairment</h2><div id="CDR0000788906__76"><h3>Nonpharmacologic Interventions</h3><p id="CDR0000788906__77">Evidence-based interventions to manage cognitive impairment in cancer patients and survivors have not been firmly established. Several nonpharmacologic approaches have shown promise, including cognitive rehabilitation, exercise, and psychosocial interventions such as attention-restoring activities and meditation.[<a class="bk_pop" href="#CDR0000788906_rl_75_1">1</a>] All of the interventions in Table 1 have shown some evidence of efficacy but remain active areas of investigation.</p><div id="CDR0000788906__99" class="table"><h3><span class="title">Table 1. Nonpharmacologic Interventions for Cognitive Impairment</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK464278.2/table/CDR0000788906__99/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000788906__99_lrgtbl__"><table class="no_margin"><thead><tr><th colspan="1" rowspan="1" style="vertical-align:top;">Intervention</th><th colspan="1" rowspan="1" style="vertical-align:top;">Dose</th><th colspan="1" rowspan="1" style="vertical-align:top;">Comments</th><th colspan="1" rowspan="1" style="vertical-align:top;">References</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" style="vertical-align:top;"><i>Cognitive rehabilitation</i></td><td colspan="1" rowspan="4" style="vertical-align:top;">4–96 h</td><td colspan="1" rowspan="1" style="vertical-align:top;">Multiple RCTs and non-RCTs showed improvement in some components of subjective/objective cognition.</td><td colspan="1" rowspan="2" style="vertical-align:top;">Positive results: [<a class="bk_pop" href="#CDR0000788906_rl_75_2">2</a>-<a class="bk_pop" href="#CDR0000788906_rl_75_13">13</a>]</td></tr><tr><td colspan="1" rowspan="3" style="vertical-align:top;">Included psychoeducation, compensatory training, and cognitive training.</td><td colspan="1" rowspan="1" style="vertical-align:top;">1 RCT and 2 non-RCTs showed no benefit.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Most RCTs had small samples (<50 participants).</td><td colspan="1" rowspan="2" style="vertical-align:top;">Negative results: [<a class="bk_pop" href="#CDR0000788906_rl_75_14">14</a>-<a class="bk_pop" href="#CDR0000788906_rl_75_16">16</a>]</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Wide variation in components of intervention, dose, and measures.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;"><i>Movement therapy</i></td><td colspan="1" rowspan="3" style="vertical-align:top;">6–36 h</td><td colspan="1" rowspan="1" style="vertical-align:top;">Several small RCTs and non-RCTs showed improvement in some components of subjective/objective cognition.</td><td colspan="1" rowspan="2" style="vertical-align:top;">Positive results: [<a class="bk_pop" href="#CDR0000788906_rl_75_2">2</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_17">17</a>-<a class="bk_pop" href="#CDR0000788906_rl_75_21">21</a>]</td></tr><tr><td colspan="1" rowspan="2" style="vertical-align:top;">Included various types of exercise, yoga, qigong, and tai chi.</td><td colspan="1" rowspan="1" style="vertical-align:top;">2 studies showed no benefit.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Wide variation in type of movement therapy, dose, and measures.</td><td colspan="1" rowspan="1" style="vertical-align:top;">Negative results: [<a class="bk_pop" href="#CDR0000788906_rl_75_22">22</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_23">23</a>]</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;"><i>Attention restoration and meditation</i></td><td colspan="1" rowspan="2" style="vertical-align:top;">12–22 h</td><td colspan="1" rowspan="2" style="vertical-align:top;">2 large RCTs and 3 small RCTs showed improvement in some components of subjective/objective cognition.</td><td colspan="1" rowspan="2" style="vertical-align:top;">Positive results: [<a class="bk_pop" href="#CDR0000788906_rl_75_24">24</a>-<a class="bk_pop" href="#CDR0000788906_rl_75_28">28</a>]</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">All therapies involved quiet, focused attention in the present moment.</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">RCT = randomized controlled trial.</p></div></dd></dl></div></div></div><div id="CDR0000788906__83"><h4>Cognitive rehabilitation (CR)</h4><p id="CDR0000788906__84">CR has shown promise in reducing the impact of cognitive problems on cancer patients and survivors. CR originated to treat populations with brain injuries such as stroke or traumatic brain injury, and it has been adapted for the cancer setting.[<a class="bk_pop" href="#CDR0000788906_rl_75_29">29</a>] Several rehabilitation approaches have been blended to varying degrees in CR interventions:</p><ul id="CDR0000788906__85"><li class="half_rhythm"><div><i>Psychoeducation</i> provides useful information about brain functioning, cognitive deficits, and their consequences for daily life.[<a class="bk_pop" href="#CDR0000788906_rl_75_4">4</a>]</div></li><li class="half_rhythm"><div><i>Compensatory training</i> focuses on the acquisition of new behaviors and strategies to compensate for chronic dysfunction. This intervention may include modifying or restructuring the environment by substituting external aids (such as calendars and electronic diaries) so that individuals rely less on their cognitive abilities; or learning new coping strategies (such as pacing cognitive activities and minimizing distractions).[<a class="bk_pop" href="#CDR0000788906_rl_75_8">8</a>]</div></li><li class="half_rhythm"><div><i>Cognitive training</i> involves the use of repetitive, increasingly challenging tasks (often via computer) to improve, maintain, or restore cognitive function in the areas of attention, memory, and executive function.[<a class="bk_pop" href="#CDR0000788906_rl_75_9">9</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_13">13</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_30">30</a>]</div></li></ul><p id="CDR0000788906__86">The modest evidence for the efficacy of CR is based on several randomized controlled trials using a diverse group of objective tests of neuropsychological function and subjective measures of cognitive impairment.[<a class="bk_pop" href="#CDR0000788906_rl_75_6">6</a>-<a class="bk_pop" href="#CDR0000788906_rl_75_9">9</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_11">11</a>] CR intervention groups showed greater improvement than did control subjects in self-reported cognitive impairment [<a class="bk_pop" href="#CDR0000788906_rl_75_6">6</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_7">7</a>] and objective neuropsychological measures of attention,[<a class="bk_pop" href="#CDR0000788906_rl_75_6">6</a>] memory,[<a class="bk_pop" href="#CDR0000788906_rl_75_7">7</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_8">8</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_11">11</a>] and processing speed.[<a class="bk_pop" href="#CDR0000788906_rl_75_11">11</a>] Other CR intervention studies provided similar results but were limited by partial or no randomization,[<a class="bk_pop" href="#CDR0000788906_rl_75_5">5</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_14">14</a>] one-group design,[<a class="bk_pop" href="#CDR0000788906_rl_75_3">3</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_4">4</a>] or secondary analysis.[<a class="bk_pop" href="#CDR0000788906_rl_75_10">10</a>]</p></div><div id="CDR0000788906__87"><h4>Physical activity</h4><p id="CDR0000788906__88">Despite interest in movement therapies to treat cognitive impairment,[<a class="bk_pop" href="#CDR0000788906_rl_75_17">17</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_19">19</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_22">22</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_31">31</a>] only a few clinical trials have been completed. A randomized controlled trial of qigong—a set of coordinated gentle exercises, meditation, and breathing—demonstrated improved self-reported cognitive impairment in cancer survivors after chemotherapy.[<a class="bk_pop" href="#CDR0000788906_rl_75_19">19</a>] Other movement studies used one-group designs,[<a class="bk_pop" href="#CDR0000788906_rl_75_22">22</a>] were not randomized,[<a class="bk_pop" href="#CDR0000788906_rl_75_21">21</a>] or were secondary analyses.[<a class="bk_pop" href="#CDR0000788906_rl_75_18">18</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_23">23</a>]</p></div><div id="CDR0000788906__89"><h4>Attention restoration</h4><p id="CDR0000788906__90">An intervention focused specifically on maintaining and restoring the capacity to direct attention, actively focus, and concentrate—components of cognitive function—was developed and tested in breast cancer survivors.[<a class="bk_pop" href="#CDR0000788906_rl_75_24">24</a>] The intervention consisted of exposure to the natural environment, including activities such as walking or sitting outdoors, tending plants or gardening, watching birds or other wildlife, and caring for pets. Participants contracted in writing to spend 120 minutes per week engaged in one or more of these activities. Neuropsychological tests of attention demonstrated greater improvement in the capacity to direct attention in the group that participated in attention-restoring activities than in the control group.[<a class="bk_pop" href="#CDR0000788906_rl_75_25">25</a>]</p></div><div id="CDR0000788906__91"><h4>Meditation</h4><p id="CDR0000788906__92">Mindfulness-based stress reduction (MBSR) is an integrative therapy that focuses on bringing attention and awareness to each moment in a nonjudgmental way. The benefits of MBSR have been evaluated in numerous studies of health conditions such as chronic pain, anxiety, and fibromyalgia.[<a class="bk_pop" href="#CDR0000788906_rl_75_26">26</a>] A review of MBSR studies in cancer patients found only two randomized trials with positive results, despite a small sample size.[<a class="bk_pop" href="#CDR0000788906_rl_75_28">28</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_32">32</a>] In one large, adequately powered, randomized trial in breast cancer survivors, the MBSR group showed more improvement in self-reported confusion than did the control group at the end of the intervention period, but there were no long-term effects.[<a class="bk_pop" href="#CDR0000788906_rl_75_26">26</a>] No objective measures of cognitive function were used in this trial, and evidence of impairment was not a requirement for study eligibility.</p><p id="CDR0000788906__93">A smaller study showed that MBSR participants experienced more positive effects on self-reported attention and working memory than did a control group; the finding was durable at 6 months.[<a class="bk_pop" href="#CDR0000788906_rl_75_28">28</a>] An objective measure of accuracy also showed durable improvement in the MBSR group.</p><p id="CDR0000788906__94">A randomized trial of Tibetan sound meditation demonstrated improvement in objective measures of memory, processing speed, and self-reported cognitive function.[<a class="bk_pop" href="#CDR0000788906_rl_75_27">27</a>] Although the sample size was small, eligibility for the study required self-reported cognitive impairment.</p></div></div><div id="CDR0000788906__95"><h3>Pharmacologic Interventions</h3><p id="CDR0000788906__100">Several classes of agents have been investigated as potential interventions for managing cognitive impairment. In general, the quality of study design, the outcomes studied, and variation in dose and schedules of the agents prevent any firm conclusions. The agents, putative mechanisms of action, and summary of results are provided below and in <a class="figpopup" href="/books/NBK464278.2/table/CDR0000788906__103/?report=objectonly" target="object" rid-figpopup="figCDR0000788906103" rid-ob="figobCDR0000788906103">Table 2</a>.</p><ul id="CDR0000788906__101"><li class="half_rhythm"><div><b>Psychostimulants.</b> Psychostimulants are approved by the U.S. Food and Drug Administration primarily for attention-deficit hyperactivity disorder or sleep-wake disorders. Generally well tolerated, these agents have been tested in individuals with drug- or cancer therapy–induced cognitive dysfunction with varying levels of other associated symptoms.[<a class="bk_pop" href="#CDR0000788906_rl_75_33">33</a>-<a class="bk_pop" href="#CDR0000788906_rl_75_35">35</a>] Seven phase II trials of different psychostimulants for treating cognitive impairment and associated symptoms were reviewed. Not all agents showed benefit; the symptoms most likely to improve were alertness, attention, and psychomotor speed. Six trials had control arms, and one reported results in a descriptive fashion. Also, some trials were in limited populations that may have had additional confounders such as individuals with central nervous system tumors, making results difficult to extrapolate to other patient groups.[<a class="bk_pop" href="#CDR0000788906_rl_75_34">34</a>-<a class="bk_pop" href="#CDR0000788906_rl_75_36">36</a>] Finally, the trials were underpowered, in part because of difficulty with enrollment.</div></li><li class="half_rhythm"><div><b>Erythropoietin-Stimulating Agents (ESAs).</b> The hypothesized mechanism for ESAs in the improvement of cognitive function is the result of preclinical data demonstrating erythropoietin receptors in brain tissue providing a neuroprotective effect, preventing neuronal apoptosis. The potential for cognitive improvement must be weighed against the risks of ESAs, including cardiovascular and thrombotic events, the potential for causing tumor progression, and decreases in overall survival.</div></li><li class="half_rhythm"><div><b>Acetylcholinesterase (AChE) Inhibitors.</b> Donepezil, an AChE inhibitor, is approved for Alzheimer disease. It is hypothesized that whole-brain radiation therapy (WBRT) causes neuronal injury that results in a decrease in acetylcholine. This theory is supported clinically by similarities between WBRT cognitive dysfunction and Alzheimer disease. The use of donepezil may increase acetylcholine levels in the brain.</div></li><li class="half_rhythm"><div><b>N-Methyl-D-Aspartate (NMDA) Receptor Antagonists.</b> By inhibiting the NMDA receptor with the antagonist memantine, radiation-induced neuronal stimulation and excitotoxicity may be reduced, thus preventing WBRT-induced cognitive decline. Memantine has not been studied for reducing cognitive dysfunction outside of the WBRT setting.</div></li></ul><div id="CDR0000788906__103" class="table"><h3><span class="title">Table 2. Agents for Managing Cognitive Impairment</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK464278.2/table/CDR0000788906__103/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000788906__103_lrgtbl__"><table class="no_margin"><thead><tr><th colspan="1" rowspan="1" style="vertical-align:top;">Agent</th><th colspan="1" rowspan="1" style="vertical-align:top;">Dose</th><th colspan="1" rowspan="1" style="vertical-align:top;">Comments</th></tr></thead><tbody><tr><td colspan="3" rowspan="1" style="vertical-align:top;"><b>Psychostimulants</b></td></tr><tr><td colspan="1" rowspan="2" style="vertical-align:top;">Methylphenidate</td><td colspan="1" rowspan="2" style="vertical-align:top;">10–30 mg/d for ≥2 d</td><td colspan="1" rowspan="1" style="vertical-align:top;">Phase II studies with varying levels of benefits for different cognitive parameters (alertness, attention, memory, psychomotor speed, and executive function).</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Small trials, not always randomized, did not always meet accrual goals; results should be interpreted with caution.[<a class="bk_pop" href="#CDR0000788906_rl_75_33">33</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_34">34</a>]; [<a class="bk_pop" href="#CDR0000788906_rl_75_36">36</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>]</td></tr><tr><td colspan="1" rowspan="3" style="vertical-align:top;">D-methylphenidate</td><td colspan="1" rowspan="3" style="vertical-align:top;">5–10 mg bid</td><td colspan="1" rowspan="1" style="vertical-align:top;">Small, underpowered, placebo-controlled experience showed no benefit in verbal learning.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">N = 57</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Placebo controlled.[<a class="bk_pop" href="#CDR0000788906_rl_75_37">37</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>]</td></tr><tr><td colspan="1" rowspan="4" style="vertical-align:top;">Modafinil</td><td colspan="1" rowspan="4" style="vertical-align:top;">200–400 mg/d for 4 d–6 wk</td><td colspan="1" rowspan="1" style="vertical-align:top;">Phase II studies with varied trial designs.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Benefit seen in psychomotor speed, memory, executive function, and attention, with largest study showing sustained benefit.[<a class="bk_pop" href="#CDR0000788906_rl_75_38">38</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>]</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Interpret with caution: accrual problems, short study duration, and inadequate power.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">No benefit seen in study in which patients served as their own controls.[<a class="bk_pop" href="#CDR0000788906_rl_75_34">34</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_35">35</a>,<a class="bk_pop" href="#CDR0000788906_rl_75_39">39</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>]</td></tr><tr><td colspan="3" rowspan="1" style="vertical-align:top;"><b>ESAs</b></td></tr><tr><td colspan="1" rowspan="2" style="vertical-align:top;">Erythropoietin</td><td colspan="1" rowspan="2" style="vertical-align:top;">40,000 U/wk</td><td colspan="1" rowspan="1" style="vertical-align:top;">Multiple clinical trials demonstrated conflicting results; no intervention effect on improvement in subjective cognitive function.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Results difficult to generalize: varying assessment tools, small sample sizes, and differences in dosing and length of treatment.[<a class="bk_pop" href="#CDR0000788906_rl_75_40">40</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>]; [<a class="bk_pop" href="#CDR0000788906_rl_75_41">41</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>]; [<a class="bk_pop" href="#CDR0000788906_rl_75_42">42</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>]; [<a class="bk_pop" href="#CDR0000788906_rl_75_43">43</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>]; [<a class="bk_pop" href="#CDR0000788906_rl_75_44">44</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>]; [<a class="bk_pop" href="#CDR0000788906_rl_75_45">45</a>]</td></tr><tr><td colspan="3" rowspan="1" style="vertical-align:top;"><b>AChE Inhibitors</b></td></tr><tr><td colspan="1" rowspan="2" style="vertical-align:top;">Donepezil</td><td colspan="1" rowspan="2" style="vertical-align:top;">5 mg qd; may increase to 10 mg qd</td><td colspan="1" rowspan="1" style="vertical-align:top;">Studied in patients 1–5 y postchemotherapy and >6 mo post-WBRT.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Mixed results of no treatment effect and some improvement in some measures of attention, concentration, and memory in each trial.[<a class="bk_pop" href="#CDR0000788906_rl_75_46">46</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>]; [<a class="bk_pop" href="#CDR0000788906_rl_75_47">47</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>]; [<a class="bk_pop" href="#CDR0000788906_rl_75_48">48</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>]</td></tr><tr><td colspan="3" rowspan="1" style="vertical-align:top;"><b>NMDA Receptor Antagonists</b></td></tr><tr><td colspan="1" rowspan="2" style="vertical-align:top;">Memantine</td><td colspan="1" rowspan="2" style="vertical-align:top;">20 mg qd</td><td colspan="1" rowspan="1" style="vertical-align:top;">One RCT; primary endpoint of improvement in delayed recall not statistically significant.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Treatment resulted in better cognitive function over time; delayed time to cognitive decline; and reduced rate of decline in memory, executive function, and processing speed.[<a class="bk_pop" href="#CDR0000788906_rl_75_49">49</a>]</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AChE = acetylcholinesterase; bid = twice a day; ESA = erythropoietin-stimulating agent; NMDA = N-methyl-D-aspartate; qd = every day; RCT = randomized controlled trial; WBRT = whole-brain radiation therapy.</p></div></dd></dl></div></div></div></div><div id="CDR0000788906_rl_75"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000788906_rl_75_1">Von Ah D: Cognitive changes associated with cancer and cancer treatment: state of the science. Clin J Oncol Nurs 19 (1): 47-56, 2015. [<a href="https://pubmed.ncbi.nlm.nih.gov/25689649" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25689649</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_2">Korstjens I, Mesters I, van der Peet E, et al.: Quality of life of cancer survivors after physical and psychosocial rehabilitation. Eur J Cancer Prev 15 (6): 541-7, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/17106335" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17106335</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_3">Ercoli LM, Castellon SA, Hunter AM, et al.: Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints. Brain Imaging Behav 7 (4): 543-53, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/23955490" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23955490</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_4">Ferguson RJ, Ahles TA, Saykin AJ, et al.: Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology 16 (8): 772-7, 2007. [<a href="/pmc/articles/PMC3482484/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3482484</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17152119" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17152119</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_5">Schuurs A, Green HJ: A feasibility study of group cognitive rehabilitation for cancer survivors: enhancing cognitive function and quality of life. Psychooncology 22 (5): 1043-9, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/22570263" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22570263</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_6">Cherrier MM, Anderson K, David D, et al.: A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci 93 (17): 617-22, 2013. [<a href="/pmc/articles/PMC3838727/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3838727</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24012579" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24012579</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_7">Ercoli LM, Petersen L, Hunter AM, et al.: Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology 24 (11): 1360-7, 2015. [<a href="https://pubmed.ncbi.nlm.nih.gov/25759235" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25759235</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_8">Ferguson RJ, McDonald BC, Rocque MA, et al.: Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology 21 (2): 176-86, 2012. [<a href="/pmc/articles/PMC3955296/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3955296</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22271538" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22271538</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_9">Kesler S, Hadi Hosseini SM, Heckler C, et al.: Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer 13 (4): 299-306, 2013. [<a href="/pmc/articles/PMC3726272/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3726272</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23647804" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23647804</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_10">McDougall GJ, Becker H, Acee TW, et al.: Symptom management of affective and cognitive disturbance with a group of cancer survivors. Arch Psychiatr Nurs 25 (1): 24-35, 2011. [<a href="/pmc/articles/PMC3057534/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3057534</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21251599" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21251599</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_11">Von Ah D, Carpenter JS, Saykin A, et al.: Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 135 (3): 799-809, 2012. [<a href="/pmc/articles/PMC3677054/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3677054</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22918524" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22918524</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_12">McDougall GJ Jr: Memory improvement program for elderly cancer survivors. Geriatr Nurs 22 (4): 185-90, 2001 Jul-Aug. [<a href="https://pubmed.ncbi.nlm.nih.gov/11505244" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11505244</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_13">Bray VJ, Dhillon HM, Bell ML, et al.: Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy. J Clin Oncol 35 (2): 217-225, 2017. [<a href="https://pubmed.ncbi.nlm.nih.gov/28056205" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28056205</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_14">Poppelreuter M, Weis J, Bartsch HH: Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. J Psychosoc Oncol 27 (2): 274-96, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19337933" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19337933</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_15">Poppelreuter M, Weis J, Mumm A, et al.: Rehabilitation of therapy-related cognitive deficits in patients after hematopoietic stem cell transplantation. Bone Marrow Transplant 41 (1): 79-90, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/17934527" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17934527</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_16">Rottmann N, Dalton SO, Bidstrup PE, et al.: No improvement in distress and quality of life following psychosocial cancer rehabilitation. A randomised trial. Psychooncology 21 (5): 505-14, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/21308859" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21308859</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_17">Reid-Arndt SA, Matsuda S, Cox CR: Tai Chi effects on neuropsychological, emotional, and physical functioning following cancer treatment: a pilot study. Complement Ther Clin Pract 18 (1): 26-30, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22196570" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22196570</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_18">Derry HM, Jaremka LM, Bennett JM, et al.: Yoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial. Psychooncology 24 (8): 958-66, 2015. [<a href="/pmc/articles/PMC4405403/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4405403</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25336068" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25336068</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_19">Oh B, Butow PN, Mullan BA, et al.: Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Support Care Cancer 20 (6): 1235-42, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/21688163" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21688163</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_20">Schmidt T, Weisser B, Dürkop J, et al.: Comparing Endurance and Resistance Training with Standard Care during Chemotherapy for Patients with Primary Breast Cancer. Anticancer Res 35 (10): 5623-9, 2015. [<a href="https://pubmed.ncbi.nlm.nih.gov/26408735" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26408735</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_21">Baumann FT, Drosselmeyer N, Leskaroski A, et al.: 12-week resistance training with breast cancer patients during chemotherapy: effects on cognitive abilities. Breast Care (Basel) 6 (2): 142-3, 2011.</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_22">Schwartz AL, Thompson JA, Masood N: Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 29 (7): E85-90, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12183762" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12183762</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_23">Schmidt ME, Wiskemann J, Armbrust P, et al.: Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial. Int J Cancer 137 (2): 471-80, 2015. [<a href="https://pubmed.ncbi.nlm.nih.gov/25484317" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25484317</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_24">Cimprich B: Development of an intervention to restore attention in cancer patients. Cancer Nurs 16 (2): 83-92, 1993. [<a href="https://pubmed.ncbi.nlm.nih.gov/8477404" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8477404</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_25">Cimprich B, Ronis DL: An environmental intervention to restore attention in women with newly diagnosed breast cancer. Cancer Nurs 26 (4): 284-92; quiz 293-4, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12886119" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12886119</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_26">Hoffman CJ, Ersser SJ, Hopkinson JB, et al.: Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial. J Clin Oncol 30 (12): 1335-42, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22430268" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22430268</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_27">Milbury K, Chaoul A, Biegler K, et al.: Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology 22 (10): 2354-63, 2013. [<a href="/pmc/articles/PMC6083855/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6083855</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23657969" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23657969</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_28">Johns SA, Von Ah D, Brown LF, et al.: Randomized controlled pilot trial of mindfulness-based stress reduction for breast and colorectal cancer survivors: effects on cancer-related cognitive impairment. J Cancer Surviv 10 (3): 437-48, 2016. [<a href="/pmc/articles/PMC4864185/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4864185</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26586494" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26586494</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_29">Cicerone KD, Dahlberg C, Malec JF, et al.: Evidence-based cognitive rehabilitation: updated review of the literature from 1998 through 2002. Arch Phys Med Rehabil 86 (8): 1681-92, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16084827" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16084827</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_30">Von Ah D, Jansen C, Allen DH, et al.: Putting evidence into practice: evidence-based interventions for cancer and cancer treatment-related cognitive impairment. Clin J Oncol Nurs 15 (6): 607-15, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/22119972" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22119972</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_31">Lee CE, Kilgour A, Lau YK: Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy. BMC Cancer 12: 324, 2012. [<a href="/pmc/articles/PMC3517385/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3517385</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22846379" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22846379</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_32">Shennan C, Payne S, Fenlon D: What is the evidence for the use of mindfulness-based interventions in cancer care? A review. Psychooncology 20 (7): 681-97, 2011. [<a href="https://pubmed.ncbi.nlm.nih.gov/20690112" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20690112</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_33">Bruera E, Miller MJ, Macmillan K, et al.: Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 48 (2): 163-6, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1589233" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1589233</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_34">Gehring K, Patwardhan SY, Collins R, et al.: A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neurooncol 107 (1): 165-74, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/21964738" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21964738</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_35">Boele FW, Douw L, de Groot M, et al.: The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro Oncol 15 (10): 1420-8, 2013. [<a href="/pmc/articles/PMC3779045/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3779045</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23925452" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23925452</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_36">Meyers CA, Weitzner MA, Valentine AD, et al.: Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16 (7): 2522-7, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9667273" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9667273</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_37">Mar Fan HG, Clemons M, Xu W, et al.: A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16 (6): 577-83, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/17972110" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17972110</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_38">Kohli S, Fisher SG, Tra Y, et al.: The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115 (12): 2605-16, 2009. [<a href="/pmc/articles/PMC2796482/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2796482</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19309747" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19309747</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_39">Lundorff LE, Jønsson BH, Sjøgren P: Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 23 (8): 731-8, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19648224" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19648224</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_40">Chang J, Couture FA, Young SD, et al.: Weekly administration of epoetin alfa improves cognition and quality of life in patients with breast cancer receiving chemotherapy. Support Cancer Ther 2 (1): 52-8, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/18628159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18628159</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_41">O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al.: Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 5 (6): 439-46, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/15748464" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15748464</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_42">Iconomou G, Koutras A, Karaivazoglou K, et al.: Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy. Eur J Cancer Care (Engl) 17 (6): 535-41, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18707621" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18707621</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_43">Fan HG, Park A, Xu W, et al.: The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology 18 (2): 156-61, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/18561284" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18561284</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_44">Massa E, Madeddu C, Lusso MR, et al.: Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol 57 (2): 175-82, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16213740" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16213740</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_45">O'Shaughnessy JA: Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 3 (Suppl 3): S116-20, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12533272" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12533272</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_46">Lawrence JA, Griffin L, Balcueva EP, et al.: A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer Surviv 10 (1): 176-84, 2016. [<a href="/pmc/articles/PMC4930878/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4930878</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26130292" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26130292</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_47">Rapp SR, Case LD, Peiffer A, et al.: Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial. J Clin Oncol 33 (15): 1653-9, 2015. [<a href="/pmc/articles/PMC4429174/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4429174</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25897156" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25897156</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_48">Shaw EG, Rosdhal R, D'Agostino RB Jr, et al.: Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 24 (9): 1415-20, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16549835" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16549835</span></a>]</div></li><li><div class="bk_ref" id="CDR0000788906_rl_75_49">Brown PD, Pugh S, Laack NN, et al.: Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15 (10): 1429-37, 2013. [<a href="/pmc/articles/PMC3779047/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3779047</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23956241" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23956241</span></a>]</div></li></ol></div></div><div id="CDR0000788906__5"><h2 id="_CDR0000788906__5_">Changes to This Summary (03/14/2018)</h2><p id="CDR0000788906__6">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</p><p id="CDR0000788906__105"><b><a href="#CDR0000788906__14">Responding to Patient Reports of Cognitive Impairment</a></b></p><p id="CDR0000788906__106">Revised <a href="/books/NBK464278.2/#CDR0000788906__16">list</a> of difficulties that cancer patients might experience to include difficulty multitasking—must focus on one thing at a time; difficulty remembering common words and recalling names; and difficulty finding words.</p><p id="CDR0000788906__107">Revised <a href="/books/NBK464278.2/#CDR0000788906__18">list</a> of potential contributing factors for cognitive impairment to include age; frailty (cited 2014 Mandelblatt et al. as reference 2 and 2016 Mandelblatt et al. as reference 3); and emotional distress and/or depressive symptoms and anxiety.</p><p id="CDR0000788906__104"><b><a href="#CDR0000788906__75">Interventions for Cognitive Impairment</a></b></p><p id="CDR0000788906__108">Added Bray et al. as <a class="figpopup" href="/books/NBK464278.2/table/CDR0000788906__99/?report=objectonly" target="object" rid-figpopup="figCDR000078890699" rid-ob="figobCDR000078890699">reference 13</a>.</p><p id="CDR0000788906__109">Revised <a href="#CDR0000788906__92">text</a> to state that a review of mindfulness-based stress reduction studies in cancer patients found only two randomized trials with positive results, despite a small same size (cited Johns et al. as reference 28).</p><p id="CDR0000788906__disclaimerHP_3">This summary is written and maintained by the <a href="http://www.cancer.gov/publications/pdq/editorial-boards/supportive-care" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Supportive and Palliative Care Editorial Board</a>, which is
|
||
editorially independent of NCI. The summary reflects an independent review of
|
||
the literature and does not represent a policy statement of NCI or NIH. More
|
||
information about summary policies and the role of the PDQ Editorial Boards in
|
||
maintaining the PDQ summaries can be found on the <a href="#CDR0000788906__AboutThis_1">About This PDQ Summary</a> and <a href="http://www.cancer.gov/publications/pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ® - NCI's Comprehensive Cancer Database</a> pages.
|
||
</p></div><div id="CDR0000788906__AboutThis_1"><h2 id="_CDR0000788906__AboutThis_1_">About This PDQ Summary</h2><div id="CDR0000788906__AboutThis_2"><h3>Purpose of This Summary</h3><p id="CDR0000788906__AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about expert-reviewed information summary about causes and management of cognitive impairment in people with cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.</p></div><div id="CDR0000788906__AboutThis_4"><h3>Reviewers and Updates</h3><p id="CDR0000788906__AboutThis_5">This summary is reviewed regularly and updated as necessary by the <a href="http://www.cancer.gov/publications/pdq/editorial-boards/supportive-care" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Supportive and Palliative Care Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="CDR0000788906__AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</p><ul id="CDR0000788906__AboutThis_6"><li class="half_rhythm"><div>be discussed at a meeting,</div></li><li class="half_rhythm"><div>be cited with text, or</div></li><li class="half_rhythm"><div>replace or update an existing article that is already cited.</div></li></ul><p id="CDR0000788906__AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.</p><p>The lead reviewers for Cognitive Impairment in Adults with Non−Central Nervous System Cancers are:</p><ul><li class="half_rhythm"><div>Andrea Barsevick, PhD (Thomas Jefferson University)</div></li><li class="half_rhythm"><div>Larry D. Cripe, MD (Indiana University School of Medicine)</div></li><li class="half_rhythm"><div>Diane Von Ah, PhD, RN, FAAN (Indiana University School of Nursing)</div></li></ul><p id="CDR0000788906__AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></div><div id="CDR0000788906__AboutThis_10"><h3>Levels of Evidence</h3><p id="CDR0000788906__AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Supportive and Palliative Care Editorial Board uses a <a href="/books/n/pdqcis/CDR0000660468/">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></div><div id="CDR0000788906__AboutThis_12"><h3>Permission to Use This Summary</h3><p id="CDR0000788906__AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</p><p id="CDR0000788906__AboutThis_14">The preferred citation for this PDQ summary is:</p><p id="CDR0000788906__AboutThis_15">PDQ® Supportive and Palliative Care Editorial Board. PDQ Cognitive Impairment in Adults with Non−Central Nervous System Cancers. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: <a href="https://www.cancer.gov/about-cancer/treatment/side-effects/cognitive-impairment-hp-pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www.cancer.gov/about-cancer/treatment/side-effects/cognitive-impairment-hp-pdq</a>. Accessed <MM/DD/YYYY>. [PMID: 29112351]</p><p id="CDR0000788906__AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Visuals Online</a>, a collection of over 2,000 scientific images.
|
||
</p></div><div id="CDR0000788906__AboutThis_17"><h3>Disclaimer</h3><p id="CDR0000788906__AboutThis_19">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Managing Cancer Care</a> page.</p></div><div id="CDR0000788906__AboutThis_20"><h3>Contact Us</h3><p id="CDR0000788906__AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website’s <a href="https://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>.</p></div></div></div></div>
|
||
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK464278</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29112351" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">29112351</a></span></div></div></div>
|
||
|
||
</div>
|
||
|
||
<!-- Custom content below content -->
|
||
<div class="col4">
|
||
|
||
</div>
|
||
|
||
|
||
<!-- Book content -->
|
||
|
||
<!-- Custom contetnt below bottom nav -->
|
||
<div class="col5">
|
||
|
||
</div>
|
||
</div>
|
||
|
||
<div id="rightcolumn" class="four_col col last">
|
||
<!-- Custom content above discovery portlets -->
|
||
<div class="col6">
|
||
<div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK464278&db=books">Share</a></div>
|
||
|
||
</div>
|
||
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK464278.2/?report=reader">PubReader</a></li><li><a href="/books/NBK464278.2/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK464278" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK464278" style="display:none" title="Cite this Page"><div class="bk_tt">PDQ Supportive and Palliative Care Editorial Board. Cognitive Impairment in Adults with Non−Central Nervous System Cancers (PDQ®): Health Professional Version. 2018 Mar 14. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. <span class="bk_cite_avail"></span></div></div></li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Version History</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter shutter_closed" title="Show/hide content" remembercollapsed="true" pgsec_name="version_history" id="Shutter"></a></div><div class="portlet_content" style="display: none;"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><span class="bk_col_itm"><a href="/books/NBK464278.16/">NBK464278.16</a></span> November 7, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK464278.15/">NBK464278.15</a></span> May 8, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK464278.14/">NBK464278.14</a></span> August 24, 2023</li><li><span class="bk_col_itm"><a href="/books/NBK464278.13/">NBK464278.13</a></span> April 14, 2023</li><li><span class="bk_col_itm"><a href="/books/NBK464278.12/">NBK464278.12</a></span> February 17, 2023</li><li><span class="bk_col_itm"><a href="/books/NBK464278.11/">NBK464278.11</a></span> November 17, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK464278.10/">NBK464278.10</a></span> March 25, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK464278.9/">NBK464278.9</a></span> November 12, 2021</li><li><span class="bk_col_itm"><a href="/books/NBK464278.8/">NBK464278.8</a></span> September 8, 2021</li><li><span class="bk_col_itm"><a href="/books/NBK464278.7/">NBK464278.7</a></span> September 3, 2021</li><li><span class="bk_col_itm"><a href="/books/NBK464278.6/">NBK464278.6</a></span> November 5, 2018</li><li><span class="bk_col_itm"><a href="/books/NBK464278.5/">NBK464278.5</a></span> October 10, 2018</li><li><span class="bk_col_itm"><a href="/books/NBK464278.4/">NBK464278.4</a></span> March 29, 2018</li><li><span class="bk_col_itm"><a href="/books/NBK464278.3/">NBK464278.3</a></span> March 20, 2018</li><li><span class="bk_col_itm">NBK464278.2</span> March 14, 2018 (Displayed Version)</li><li><span class="bk_col_itm"><a href="/books/NBK464278.1/">NBK464278.1</a></span> November 2, 2017</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this Page</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#CDR0000788906__1" ref="log$=inpage&link_id=inpage">General Information About Cognitive Impairment in Cancer Survivors</a></li><li><a href="#CDR0000788906__10" ref="log$=inpage&link_id=inpage">Normal Cognition</a></li><li><a href="#CDR0000788906__14" ref="log$=inpage&link_id=inpage">Responding to Patient Reports of Cognitive Impairment</a></li><li><a href="#CDR0000788906__25" ref="log$=inpage&link_id=inpage">Proactive Approaches to Cognitive Impairment</a></li><li><a href="#CDR0000788906__34" ref="log$=inpage&link_id=inpage">Research Studies on Prevalence, Risk Factors, and the Natural History of Cognitive Impairment</a></li><li><a href="#CDR0000788906__75" ref="log$=inpage&link_id=inpage">Interventions for Cognitive Impairment</a></li><li><a href="#CDR0000788906__5" ref="log$=inpage&link_id=inpage">Changes to This Summary (03/14/2018)</a></li><li><a href="#CDR0000788906__AboutThis_1" ref="log$=inpage&link_id=inpage">About This PDQ Summary</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related publications</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK488098/">Patient Version</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&DbFrom=books&Cmd=Link&LinkName=books_pmc_refs&IdsFromResult=4467546" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&DbFrom=books&Cmd=Link&LinkName=books_pubmed_refs&IdsFromResult=4467546" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389370" ref="ordinalpos=1&linkpos=1&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Communication in Cancer Care (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Communication in Cancer Care (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Supportive and Palliative Care Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389484" ref="ordinalpos=1&linkpos=2&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fatigue (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fatigue (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Supportive and Palliative Care Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389173" ref="ordinalpos=1&linkpos=3&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Delirium (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Delirium (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Supportive and Palliative Care Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389207" ref="ordinalpos=1&linkpos=4&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Smoking in Cancer Care (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Smoking in Cancer Care (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Supportive and Palliative Care Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389413" ref="ordinalpos=1&linkpos=5&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Levels of Evidence for Supportive and Palliative Care Studies (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Levels of Evidence for Supportive and Palliative Care Studies (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Supportive and Palliative Care Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed_reviews&uid=29112351" ref="ordinalpos=1&log$=relatedreviews_seeall&logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed&uid=29112351" ref="ordinalpos=1&log$=relatedarticles_seeall&logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=67c97dd4ab82281a8078be65">Cognitive Impairment in Adults with Non−Central Nervous System Cancers (PDQ®) - ...</a><div class="ralinkpop offscreen_noflow">Cognitive Impairment in Adults with Non−Central Nervous System Cancers (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=2" href="/portal/utils/pageresolver.fcgi?recordid=67c97dd0b15b832ebc47b8cb">Cognitive Impairment in Adults With Non−Central Nervous System Cancers (PDQ®) - ...</a><div class="ralinkpop offscreen_noflow">Cognitive Impairment in Adults With Non−Central Nervous System Cancers (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=3" href="/portal/utils/pageresolver.fcgi?recordid=67c97dccf4a390645e720a88">Cognitive Impairment in Adults With Cancer (PDQ®) - PDQ Cancer Information Summa...</a><div class="ralinkpop offscreen_noflow">Cognitive Impairment in Adults With Cancer (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_qry two_line"><a class="htb" ref="log$=activity&linkpos=4" href="/portal/utils/pageresolver.fcgi?recordid=67c97da8f4a390645e70fa04">PMC Links for Books (Select 5606490) <span class="number">(12)</span></a><div class="tertiary">PMC</div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=5" href="/portal/utils/pageresolver.fcgi?recordid=67c97da7f4a390645e70f245">Rhabdoid Tumor Predisposition Syndrome Type 1 (PDQ®) - PDQ Cancer Information Su...</a><div class="ralinkpop offscreen_noflow">Rhabdoid Tumor Predisposition Syndrome Type 1 (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
|
||
|
||
<!-- Custom content below discovery portlets -->
|
||
<div class="col7">
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- Custom content after all -->
|
||
<div class="col8">
|
||
|
||
</div>
|
||
<div class="col9">
|
||
|
||
</div>
|
||
|
||
<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
|
||
<script type="text/javascript">
|
||
(function($){
|
||
$('.skiplink').each(function(i, item){
|
||
var href = $($(item).attr('href'));
|
||
href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
|
||
$(item).on('click', function(event){
|
||
event.preventDefault();
|
||
$.scrollTo(href, 0, {
|
||
onAfter: function(){
|
||
href.focus();
|
||
}
|
||
});
|
||
});
|
||
});
|
||
})(jQuery);
|
||
</script>
|
||
</div>
|
||
<div class="bottom">
|
||
|
||
<div id="NCBIFooter_dynamic">
|
||
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
||
<component id="Breadcrumbs" label="helpdesk"/>-->
|
||
|
||
</div>
|
||
|
||
<div class="footer" id="footer">
|
||
<section class="icon-section">
|
||
<div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
|
||
<div class="grid-container container">
|
||
<div class="icon-section_container">
|
||
<a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
||
<defs>
|
||
<style>
|
||
.cls-11 {
|
||
fill: #737373;
|
||
}
|
||
</style>
|
||
</defs>
|
||
<title>Twitter</title>
|
||
<path class="cls-11" d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
|
||
</path>
|
||
</svg></a>
|
||
<a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
||
<title>Facebook</title>
|
||
<path class="cls-11" d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
|
||
</path>
|
||
</svg></a>
|
||
<a class="footer-icon" id="footer_linkedin" href="https://www.linkedin.com/company/ncbinlm" aria-label="LinkedIn"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
||
<title>LinkedIn</title>
|
||
<path class="cls-11" d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
|
||
</path>
|
||
</svg></a>
|
||
<a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
||
<defs>
|
||
<style>
|
||
.cls-11,
|
||
.cls-12 {
|
||
fill: #737373;
|
||
}
|
||
|
||
.cls-11 {
|
||
fill-rule: evenodd;
|
||
}
|
||
</style>
|
||
</defs>
|
||
<title>GitHub</title>
|
||
<path class="cls-11" d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
|
||
</path>
|
||
<path class="cls-12" d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
|
||
</path>
|
||
<path class="cls-12" d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
|
||
</path>
|
||
<path class="cls-12" d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
|
||
<path class="cls-12" d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
|
||
</path>
|
||
<path class="cls-12" d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
|
||
</path>
|
||
<path class="cls-12" d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
|
||
</path>
|
||
<path class="cls-12" d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
|
||
</svg></a>
|
||
<a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
|
||
<svg xmlns="http://www.w3.org/2000/svg" id="Layer_1" data-name="Layer 1" viewBox="0 0 40 40">
|
||
<defs><style>.cls-1{fill:#737373;}</style></defs>
|
||
<title>NCBI Insights Blog</title>
|
||
<path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"></path>
|
||
</svg>
|
||
</a>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<section class="container-fluid bg-primary">
|
||
<div class="container pt-5">
|
||
<div class="row mt-3">
|
||
<div class="col-lg-3 col-12">
|
||
<p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
|
||
<ul class="list-inline social_media">
|
||
<li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
||
<style type="text/css">
|
||
.st20 {
|
||
fill: #FFFFFF;
|
||
}
|
||
|
||
.st30 {
|
||
fill: none;
|
||
stroke: #FFFFFF;
|
||
stroke-width: 8;
|
||
stroke-miterlimit: 10;
|
||
}
|
||
</style>
|
||
<title>Twitter</title>
|
||
<g>
|
||
<g>
|
||
<g>
|
||
<path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7 c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116 c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3 c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6 C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
|
||
</g>
|
||
</g>
|
||
<circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
|
||
</g>
|
||
</svg></a></li>
|
||
<li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine" aria-label="Facebook" rel="noopener noreferrer" target="_blank">
|
||
<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
||
<style type="text/css">
|
||
.st10 {
|
||
fill: #FFFFFF;
|
||
}
|
||
|
||
.st110 {
|
||
fill: none;
|
||
stroke: #FFFFFF;
|
||
stroke-width: 8;
|
||
stroke-miterlimit: 10;
|
||
}
|
||
</style>
|
||
<title>Facebook</title>
|
||
<g>
|
||
<g>
|
||
<path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9 v67.5H135v-67.5h21.7L159,99.1z"></path>
|
||
</g>
|
||
</g>
|
||
<circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
|
||
</svg>
|
||
</a></li>
|
||
<li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
||
<title>Youtube</title>
|
||
<style type="text/css">
|
||
.st4 {
|
||
fill: none;
|
||
stroke: #FFFFFF;
|
||
stroke-width: 8;
|
||
stroke-miterlimit: 10;
|
||
}
|
||
|
||
.st5 {
|
||
fill: #FFFFFF;
|
||
}
|
||
</style>
|
||
<circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
|
||
<g transform="translate(0,-952.36218)">
|
||
<path class="st5" d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7 v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
|
||
</g>
|
||
</svg></a></li>
|
||
</ul>
|
||
</div>
|
||
<div class="col-lg-3 col-12">
|
||
<p class="address_footer text-white">National Library of Medicine<br />
|
||
<a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323" class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br />
|
||
Bethesda, MD 20894</a></p>
|
||
</div>
|
||
<div class="col-lg-3 col-12 centered-lg">
|
||
<p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br />
|
||
<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="text-white">FOIA</a><br />
|
||
<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
|
||
</div>
|
||
<div class="col-lg-3 col-12 centered-lg">
|
||
<p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br />
|
||
<a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br />
|
||
<a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
|
||
</div>
|
||
</div>
|
||
<div class="row">
|
||
<div class="col-lg-12 centered-lg">
|
||
<nav class="bottom-links">
|
||
<ul class="mt-3">
|
||
<li>
|
||
<a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
|
||
</li>
|
||
<li>
|
||
<a class="text-white" href="https://www.nih.gov/">NIH</a>
|
||
</li>
|
||
<li>
|
||
<a class="text-white" href="https://www.hhs.gov/">HHS</a>
|
||
</li>
|
||
<li>
|
||
<a class="text-white" href="https://www.usa.gov/">USA.gov</a>
|
||
</li>
|
||
</ul>
|
||
</nav>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<!--/.page-->
|
||
</div>
|
||
<!--/.wrap-->
|
||
</div><!-- /.twelve_col -->
|
||
</div>
|
||
<!-- /.grid -->
|
||
|
||
<span class="PAFAppResources"></span>
|
||
|
||
<!-- BESelector tab -->
|
||
|
||
|
||
|
||
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK464278&ncbi_domain=pdqcis&ncbi_report=record&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK464278.2/&ncbi_pagename=Cognitive Impairment in Adults with Non−Central Nervous System Cancers (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf&ncbi_bookparttype=chapter&ncbi_app=bookshelf" /></noscript>
|
||
|
||
|
||
<!-- usually for JS scripts at page bottom -->
|
||
<!--<component id="PageFixtures" label="styles"></component>-->
|
||
|
||
|
||
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
||
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
||
|
||
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4209313/4212053/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
|
||
</html> |